34284-87-2

Basic information

• Product Name: 6-METHYLAMINOURACIL
• Synonyms: 6-METHYLAMINOURACIL;2,4(1H,3H)-Pyrimidinedione, 6-(methylamino)- (9CI);NSC81005;6-(methylamino)pyrimidine-2,4(1H,3H)-dione;6-(Methylamino)-2,4(1H,3H)-pyrimidinedione;6-Methylamino-1H-pyrimidine-2,4-dione
• CAS NO: 34284-87-2
• Molecular Formula: C₅H₇N₃O₂
• Molecular Weight: 141.13
• Product Categories: PYRIMIDINE
• Mol File: 34284-87-2.mol
• Article Data: 8

Chemical Properties

• Melting Point: 300-302℃
• Appearance: /
• Density: 1.36
• Refractive Index: 1.569
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-METHYLAMINOURACIL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYLAMINOURACIL(34284-87-2)
• EPA Substance Registry System: 6-METHYLAMINOURACIL(34284-87-2)

Safety Data

• Hazardous Substances Data: 34284-87-2(Hazardous Substances Data)

Usage

General Description

6-Methylaminouracil is a chemical compound that belongs to the class of organic compounds known as pyrimidines and purines. It is a white crystalline solid that is commonly used in the synthesis of different pharmaceuticals and dyes. 6-Methylaminouracil has applications in the field of chemistry as well, being used as a precursor in the synthesis of other compounds. Its structure consists of a pyrimidine ring with a methyl group attached to the sixth position and an amino group attached to the nitrogen at position one. 6-METHYLAMINOURACIL is an important building block in the production of various pharmaceuticals and other organic compounds.

InChI:InChI=1/C5H7N3O2/c1-6-3-2-4(9)8-5(10)7-3/h2H,1H3,(H3,6,7,8,9,10)

Upstream product

• 4270-27-3 6-chlorouracil 
• 74-89-5 methylamine 
• 3764-01-0 2,4,6-trichloropyrimidine 
• 55441-71-9 9-methyluric acid 
• 32998-03-1 (2,6-dichloro-pyrimidin-4-yl)-methyl-amine 
• 856974-71-5 (2,6-bis-benzyloxy-pyrimidin-4-yl)-methyl-amine 

Downstream Products

• 98629-81-3 5,5'-<4'-nitro-1,1'-biphenyl>-4-ylmethylenebis(6-methylaminouracil) 
• 98629-79-9 5,5'-p-chlorophenylmethylenebis(6-methylaminouracil) 
• 98629-80-2 5,5'-p-nitrophenylmethylenebis(6-methylaminouracil) 
• 98629-82-4 5,5'-<4'-chloro-1,1'-biphenyl>-4-ylmethylenebis(6-methylaminouracil) 
• 98629-83-5 5,5'-<1,1'-biphenyl>-4-yl-methylenebis(6-methylaminouracil) 
• 27132-53-2 10-Methyl-5-deaza-iso-alloxazin 

Relevant articles and documents

Application of chromatography. XXXI. Structure of a green fluorescent substance produced by Eremothecium ashbyii.

-

PYRIMIDINES. II. SYNTHESIS OF 6-FLUOROURACIL.

-

Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II

The recently discovered enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2) has been implicated in the topoisomerase-mediated repair of DNA damage. In the clinical setting, it has been hypothesized that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide. Therefore, selective pharmacological inhibition of TDP2 is proposed as a novel approach to overcome intrinsic or acquired resistance to topo II-targeted drug therapy. Following a high-throughput screening (HTS) campaign, toxoflavins and deazaflavins were identified as the first reported sub-micromolar and selective inhibitors of this enzyme. Toxoflavin derivatives appeared to exhibit a clear structure-activity relationship (SAR) for TDP2 enzymatic inhibition. However, we observed a key redox liability of this series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, precluded further exploration. The deazaflavins were developed from a singleton HTS hit. This series showed distinct SAR and did not display redox activity; however low cell permeability proved to be a challenge.

Synthesis, biological active molecular design, and molecular docking study of novel deazaflavin-cholestane hybrid compounds

Novel deazaflavin-cholestane hybrid compounds, 3′,8′-disubstituted-5′-deazacholest-2,4-dieno[2,3-g]pteridine-2′,4′(3′H,8′H)-diones, have been synthesized by condensation reaction between 6-(monosubstituted amino)-pyrimidin-2,4(1H,3H)-diones and 2-hydroxymethylenecholest-4-en-3-one in presence of p-toluenesulfonic acid monohydrate and diphenyl ether. The antitumor activities against human tumor cell lines (CCRF-HSB-2 and KB cells) have been investigated in vitro, and many of these compounds showed promising antitumor activities. Furthermore, molecular docking study using LigandFit within the software package Discovery Studio 1.7 was done for lead optimization of these compounds as potential PTK inhibitors. In general, all of the synthesized steroid-hybrid compounds showed good binding affinities into PTK (PDB code: 1t46).